Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
Some adverse reactions from Nexavar typically occur early in the course of treatment. Proactive management before and throughout patients' treatment is important, as it may help decrease symptom severity and allow patients to maintain the benefit of therapy.1-3
Treatment interruption and/or dose reduction may be needed to manage suspected adverse drug reactions. The Nexavar dose may be reduced to 400 mg once daily or to 400 mg every other day. Management of common adverse reactions may require dose reduction, temporary interruption, or in severe or persistent cases, permanent discontinuation of Nexavar therapy.
Patients should be instructed to contact their health care provider's office immediately if experiencing any adverse reactions.Read more about:
References: 1. Wood LS. Managing the side effects of sorafenib and sunitinib. Commun Oncol. 2006;3(9):558-562. 2. Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nursing. 2003;7(6):suppl:21-24. 3. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001-1011.